BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15580400)

  • 1. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
    Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
    J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
    Imazeki F; Yokosuka O; Fukai K; Saisho H
    Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
    Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.
    Kasahara A; Tanaka H; Okanoue T; Imai Y; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
    J Viral Hepat; 2004 Mar; 11(2):148-56. PubMed ID: 14996350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
    Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
    Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
    Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.
    Fontana RJ; Israel J; LeClair P; Banner BF; Tortorelli K; Grace N; Levine RA; Fiarman G; Thiim M; Tavill AS; Bonkovsky HL
    Hepatology; 2000 Mar; 31(3):730-6. PubMed ID: 10706565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
    Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
    Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
    Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
    J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study.
    Coverdale SA; Khan MH; Byth K; Lin R; Weltman M; George J; Samarasinghe D; Liddle C; Kench JG; Crewe E; Farrell GC
    Am J Gastroenterol; 2004 Apr; 99(4):636-44. PubMed ID: 15089895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Aug; 79(8):1095-102. PubMed ID: 17597485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
    Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.